Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
President Donald Trump on Thursday announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatments. The agreements will cut prices of so-called GLP-1 drugs for Medicare and Medicaid beneficiaries in 2026 and […]
New Guidance on Resmetirom and Semaglutide for MASH
(MedPage Today) — At the American Association for the Study of Liver Diseases (AASLD) annual meeting, a session highlighted new guidance on using resmetirom (Rezdiffra) and semaglutide (Ozempic, Wegovy) for metabolic dysfunction-associated steatohepatitis…
KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use – KFF
KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use KFF
Systematic review regarding using GLP 1 in pediatric obesity research
I am preparing a systematic review for journal submission that examines how GLP-1 receptor agonists perform against alternative treatments in managing pediatric obesity. The manuscript must be rigorous… (Budget: $30 – $250 USD, Jobs: Data Analysis, Medical Writing, Research, Research Writing, Scientific Writing, Statistical Analysis, Technical Writing)
Hospital supply chain pressures mount: 7 trends to watch
Hospitals may face renewed supply chain pressure heading into 2026, including rising material costs to tariff-driven disruptions. Here are seven developments leaders should watch: 1. Medical supply chain expenses are expected to rise more than previously projected. Vizient’s Summer 2025 Spend Management Outlook now forecasts a 2.41% increase in 2026, up from the 2.3% estimate […]
GLP-1s Tied to Big Survival Advantage in Colon Cancer Patients
(MedPage Today) — Patients with colon cancer and a history of treatment with GLP-1 receptor agonists for obesity had a 5-year mortality rate that was less than half the rate for patients who didn’t take these drugs, according to a large retrospective…
Americans are injecting themselves with unproven peptides sold by influencers and RFK Jr. allies
By MATTHEW PERRONE, Associated Press Health Writer WASHINGTON (AP) — More Americans are injecting themselves with unapproved chemicals that are pitched as ways to build muscle, rejuvenate skin and extend life, the latest example of the nation’s fascination with alternative therapies and wellness hacks. Behind the trend is the surging popularity of GLP-1 weight loss medications, a class of so-called […]
Breaking Down the Beauty Industry 2025 By the Numbers
Presenting the latest installment of W’s column By the Numbers, where we explore a given field—from art and fashion to music and movies—through the essential and eccentric metrics that define it. For W’s annual Originals Issue, we look at the beauty industry, covering everything from facelifts for the young to diamond-encrusted lipstick. Photo by KMazur/WireImage […]
Can Lilly’s Next-Gen Obesity Drugs Help Sustain Its Market Dominance?
Eli Lilly and Company LLY is one of the two companies that dominate the booming diabetes and obesity space, driven by its successful GLP-1 therapies — Mounjaro for diabetes and Zepbound for weight loss, both comprising the same ingredient, tirzepatide, a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA). Mounjaro and Zepbound face strong competition […]
Meghan Trainor Fires Back at Body-Shamers After Losing 60 Pounds
Meghan Trainor is defending her weight loss. In a new interview, the 31-year-old “Made You Look” singer fired back at body-shamers who have “attacked” her over her 60-pound weight loss and made it clear that she is perfectly healthy. Keep reading to find out more…“I’m literally for the first time ever, after having babies, taking […]